TWV Podcast Episode 444: Covid-19 Vaccine Myths and FAQ Part 4

This week’s episode of The Whole View podcast finally wraps up our 4-part series on the covid-19 mRNA vaccines! In this episode, Stacy and I answer your remaining FAQ, including about hematopoietic stem cell toxicity and antibody-enhanced infection, and address the most pervasive myths about these vaccines. We conclude by summarizing distribution challenges, inequities and priorities, as well as how to support your immune system upon vaccination.

Table of Contents[Hide][Show]

Recommended Reading and Listening
Citations

If you enjoy the show, please review it on iTunes!

Citations

King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol. 2011 Sep 9;11(10):685-92. doi: 10.1038/nri3062. PMID: 21904387; PMCID: PMC4154310.

Zhang CC. Hematopoietic stem cells: interplay with immunity. Am J Blood Res. 2012;2(4):219-27. Epub 2012 Nov 25. PMID: 23226622; PMCID: PMC3512180.

Li YD, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020 Dec 20;27(1):104. doi: 10.1186/s12929-020-00695-2. PMID: 33341119; PMCID: PMC7749790.

United States vaccine research: a delicate fabric of public and private collaboration. National Vaccine Advisory Committee. Pediatrics. 1997 Dec;100(6):1015-20. doi: 10.1542/peds.100.6.1015. PMID: 9411380.

Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261-279. doi: 10.1038/nrd.2017.243. Epub 2018 Jan 12. PMID: 29326426; PMCID: PMC5906799.

Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA Vaccines for Infectious Diseases. Front Immunol. 2019 Mar 27;10:594. doi: 10.3389/fimmu.2019.00594. PMID: 30972078; PMCID: PMC6446947.

Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319-34. doi: 10.4155/tde-2016-0006. Erratum in: Ther Deliv. 2016 Jun;7(6):411. PMID: 27075952; PMCID: PMC5439223.

Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020 Feb 4;5:11. doi: 10.1038/s41541-020-0159-8. PMID: 32047656; PMCID: PMC7000814.

Save 70% Off the AIP Lecture Series!

Learn everything you need to know about the Autoimmune Protocol to regain your health!

I am loving this AIP course and all the information I am receiving. The amount of work you have put into this is amazing and greatly, GREATLY, appreciated. Thank you so much. Taking this course gives me the knowledge I need to understand why my body is doing what it is doing and reinforces my determination to continue along this dietary path to heal it. Invaluable!

Carmen Maier

Save 70%

Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19. PMID: 25233993.

Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020 Nov 14;396(10262):1595-1606. doi: 10.1016/S0140-6736(20)32137-1. Epub 2020 Oct 13. PMID: 33065034; PMCID: PMC7553736.

FDA Briefing Document (54 pages)

Published Phase 1 trial result

Published Phase 2/3 trial results

FDA Briefing Document (92 pages)

Published Phase 1 trial results

Published Phase 2/3 trial results